Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New Haven, CT, US. The stock last traded at $17.93, up 0.76% on the session, giving a market capitalisation of $2.55B. On trailing twelve-month figures it carries a trailing P/E of -53.09, a net margin of 0.0%. Its beta of 1.07 implies it has historically moved more than the broad market.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Trevi Therapeutics, Inc. is most often compared with the following Healthcare names: